Next Article in Journal
Using Unannounced Standardized Patients to Assess the Quality of Tuberculosis Care and Antibiotic Prescribing: A Cross-Sectional Study on a Low/Middle-Income Country, Pakistan
Previous Article in Journal
Synthesis and Evaluation of Colchicine C-Cyclic AmineDerivatives as Potent Anti-Biofilms Agents AgainstMethicillin-Resistant Staphylococcus aureus
Previous Article in Special Issue
FDA-Approved Antibacterials and Echinocandins
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147

by
Natalia Roson-Calero
1,2,
Jimmy Lucas
1,
María A. Gomis-Font
3,4,
Roger de Pedro-Jové
1,
Antonio Oliver
3,4,
Clara Ballesté-Delpierre
3,5 and
Jordi Vila
1,2,3,5,*
1
Barcelona Institute for Global Health (ISGlobal), 08036 Barcelona, Spain
2
Department of Basic Clinical Practice, School of Medicine, University of Barcelona, 08036 Barcelona, Spain
3
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto Salud Carlos III, 28029 Madrid, Spain
4
Department of Microbiology, Hospital Universitario Son Espases, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
5
Department of Clinical Microbiology, Biomedical Diagnostic Center, Hospital Clinic, 08036 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Antibiotics 2025, 14(2), 174; https://doi.org/10.3390/antibiotics14020174
Submission received: 15 January 2025 / Accepted: 24 January 2025 / Published: 11 February 2025

1. Error in Figure

In the original publication [1], there was a mistake in Figure 1 as published. The molecule represented in Figure 1 is inaccurate, as the order of the amino acids is reversed, and the amine group of D-Pro(NH2) must be eliminated. The corrected Figure 1 appears below.

2. Text Correction

There was an error in the original publication [1]. The sequence of MV6 specified in the Section “2.1. MV6 Structure” is incorrect. It includes an additional amino group in the first D-Proline composing the peptide. Additionally, the correct pattern of MV6 is Arg-D-Pro-Trp, not Trp-D-Pro-Arg.
A correction has been made to Section 2. Results, “2.1. MV6 Structure”, first paragraph:
The MV6 cyclic peptide was selected for further study against A. baumannii from a synthetic library of 28 cyclic peptides following a small-scale “shot in the dark” approach in which each peptide was tested in combination with various antibiotics and bacterial species. Its structure consists of six amino acids, two arginine residues (Arg), two D-proline residues (D-Pro), and two tryptophan residues (Trp), arranged in a cyclic configuration. The final structure is &Arg-D-Pro-Trp-Arg-D-Pro-Trp& (Figure 1).
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Roson-Calero, N.; Lucas, J.; Gomis-Font, M.A.; de Pedro-Jové, R.; Oliver, A.; Ballesté-Delpierre, C.; Vila, J. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147. [Google Scholar] [CrossRef]
Figure 1. Chemical structure of MV6 cyclic peptide.
Figure 1. Chemical structure of MV6 cyclic peptide.
Antibiotics 14 00174 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Roson-Calero, N.; Lucas, J.; Gomis-Font, M.A.; de Pedro-Jové, R.; Oliver, A.; Ballesté-Delpierre, C.; Vila, J. Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147. Antibiotics 2025, 14, 174. https://doi.org/10.3390/antibiotics14020174

AMA Style

Roson-Calero N, Lucas J, Gomis-Font MA, de Pedro-Jové R, Oliver A, Ballesté-Delpierre C, Vila J. Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147. Antibiotics. 2025; 14(2):174. https://doi.org/10.3390/antibiotics14020174

Chicago/Turabian Style

Roson-Calero, Natalia, Jimmy Lucas, María A. Gomis-Font, Roger de Pedro-Jové, Antonio Oliver, Clara Ballesté-Delpierre, and Jordi Vila. 2025. "Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147" Antibiotics 14, no. 2: 174. https://doi.org/10.3390/antibiotics14020174

APA Style

Roson-Calero, N., Lucas, J., Gomis-Font, M. A., de Pedro-Jové, R., Oliver, A., Ballesté-Delpierre, C., & Vila, J. (2025). Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147. Antibiotics, 14(2), 174. https://doi.org/10.3390/antibiotics14020174

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop